ACVR and ECVDI consensus statement for the standardization of the abdominal ultrasound examination

Seiler, Gabriela; Cohen, Eli B.; d’Anjou, Marc-André; French, John K.; Gaschen, Lorrie; Knapp, Stephanie; Salwei, Rochelle M.; Saunders, Helen

doi:10.1111/vru.13151

Cited by 9 publications

(11 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A complete AUS, consistent with the criteria outlined in the ACVR and ECVDI consensus statement, was performed at each visit. 20 All AUS procedures were performed on a Canon Aplio i700 ultrasound (Canon Medical Systems USA, Inc, Tustin, CA) by a board‐certified radiologist or a trained sonographer with extensive experience in veterinary ultrasonography. When the initial AUS was performed by the sonographer, a board‐certified internal medicine specialist or radiologist reviewed images to confirm study eligibility.…”

Section: Methodsmentioning

confidence: 99%

Serial monitoring of pancreatic lipase immunoreactivity, C‐reactive protein, abdominal ultrasonography, and clinical severity in dogs with suspected pancreatitis

Mitchell,

Wang,

Lawver

et al. 2024

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundDiagnosis of pancreatitis is based on clinical signs, pancreatic lipase immunoreactivity (cPLI), and abdominal ultrasonography (AUS). Diagnostic discrepancies exist between test results which might be related to differences in the timeline for resolution of these abnormalities after pancreatic injury.Hypothesis/ObjectivesTo evaluate disease severity, ultrasonographic findings, and serum biomarkers of pancreatitis in dogs over a period of 28‐days.AnimalsSixteen client‐owned dogs with a clinical suspicion for acute pancreatitis based on history/physical examination, an abnormal SNAP cPLI, and ultrasonographic evidence of pancreatitis.MethodsProspective observational study. Clinical severity (modified clinical activity index [MCAI]), cPLI, C‐reactive protein (CRP), and AUS were evaluated at days 0, 2, 7, and 28. Owner assessed overall health (OH) was noted. Dogs were stratified into baseline cPLI ≥400 μg/L vs <400 μg/L groups for reporting.ResultsThe median CRP, MCAI, and OH were 111.9 mg/L, 10, and 4/10 respectively in the cPLI ≥400 μg/L group. The median CRP, MCAI, and OH were 58.0 mg/L, 6, and 6/10 respectively in the cPLI <400 μg/L group. None of these variables were significantly different between groups. Most dogs (4/5) in the cPLI <400 μg/L group had a history of suspected pancreatitis (ie, suspect acute on chronic disease). cPLI and MCAI rapidly decreased in dogs with a baseline cPLI ≥400 μg/L, whereas sonographic evidence of pancreatitis persisted for a longer time period.Conclusions and Clinical ImportanceUltrasonographic evidence of pancreatitis in the absence of overt clinical or biochemical abnormalities might represent a resolving injury rather than active disease.

show abstract

Section: Methodsmentioning

confidence: 99%

Serial monitoring of pancreatic lipase immunoreactivity, C‐reactive protein, abdominal ultrasonography, and clinical severity in dogs with suspected pancreatitis

Mitchell,

Wang,

Lawver

et al. 2024

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…A single board‐certified anatomic pathologist (NMP) reviewed the histopathologic slides of all 19 cases and formulated pathological scores for grade (inflammation, necrosis) and stage (fibrosis), based on established criteria 1,11 . Ultrasound images and video clips from dogs were reviewed by a board‐certified veterinary radiologist (LAS) using the American College of Veterinary Radiology ultrasound consensus statement as a guideline 12 . In brief, the liver was evaluated for size, margination, echogenicity and the presence of focal parenchymal lesions.…”

Section: Methodsmentioning

confidence: 99%

Characterization of clinical presentation, histological features, ultrasonographic findings, and survival in 29 dogs with granulomatous hepatitis

Prentice,

Callahan‐Clark,

Parry

et al. 2023

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundGranulomatous hepatitis (GH) is a form of chronic hepatitis (CH) in dogs for which limited information is published.HypothesisDescribe the clinical presentation, clinical pathology, ultrasound, and hepatic histopathology findings and to report survival times in dogs with GH.AnimalsTwenty‐nine client‐owned dogs with GH.MethodsRetrospective observational study. Pathology records were searched. Inclusion criteria included a histopathologic diagnosis of GH, absence of an identified etiology or evidence of extrahepatic granulomatous disease, and a medical record available for review. Clinical presentation, clinical pathologic findings, treatment protocols, and survival times were recorded. Available hepatic biopsy material was graded and scored, and ultrasound evaluations reviewed.ResultsThe median age was 7 years (range, 0.66‐12 years). Nineteen breeds were represented. Decreased appetite (19/29), lethargy (16/29), and fever (13/29) were seen most commonly. All dogs had increased serum transaminase activities, whereas 21/29 and 12/24 had hyperbilirubinemia and neutrophilia, respectively. Ultrasonographic findings included hepatomegaly (12/22), nodular parenchymal lesions (9/22), and hyperechoic parenchymal bands (8/22). Histopathologic necroinflammatory scores were moderate to severe in 16/19 dogs, and fibrosis scores were mild in 14/19 dogs. Treatments varied and included antibiotics, immunosuppressive drugs, and hepatoprotectants. Overall median survival was 635 days (range, 1‐2482 days).Conclusion and Clinical ImportanceGranulomatous hepatitis in dogs is associated with high histopathologic grade, fever, neutrophilia, and a high incidence of hepatomegaly and focal parenchymal lesions on ultrasound examination. Despite disease severity on presentation, dogs with GH can have a good outcome with prolonged survival.

show abstract

“…The Veterinary Radiation Therapy Oncology Group (VRTOG) has published a radiation morbidity scoring scheme which is broadly used in the veterinary radiation oncology literature, and which could be used in the standardized scoring of side effects from radiopharmaceutical therapy 68 . A VRTOG committee has recently published an updated scoring scheme to improve precision in this side effect reporting 69 . Keyerleber et al published on improving standardization of reporting prescription and delivery parameters in the veterinary radiation oncology literature 70 .…”

Section: The Translational Value Of Companion Animal Radiopharmaceuti...mentioning

confidence: 99%

The role of companion animal models in radiopharmaceutical development and translation

Maitz,

Bryan

2024

Vet Comparative Oncology

View full text Add to dashboard Cite

Advancements in molecular imaging and drug targeting have created a renaissance in the development of radiopharmaceuticals for therapy and theranostics. While some radiopharmaceuticals, such as Na[131I]I, have been used clinically for decades, new agents are being approved using small‐molecules, peptides, and antibodies for targeting. As these agents are being developed, the need to understand dosimetry and biologic effects of the systemically delivered radiotherapy becomes more important, particularly as highly potent radiopharmaceuticals using targeted alpha therapy become clinically utilized. As the processes being targeted become more complex, and the radiobiology of different particulate radiation becomes more diverse, models that better recapitulate human cancer and geometry are necessary. Companion animals develop many of the same types of cancer, carrying many of the same genetic drivers as those seen in people, and the scale and geometry of tumours in dogs more closely mimics those in humans than murine tumour models. Key translational challenges in oncology, such as alterations in tumour microenvironment, hypoxia, heterogeneity, and geometry are addressed by companion animal models. This review paper will provide background on radiopharmaceutical targeting techniques, review the use of radiopharmaceuticals in companion animal oncology, and explore the translational value of treating these patients in terms of dosimetry, treatment outcomes, and normal tissue complication rates.

show abstract

ACVR and ECVDI consensus statement for the standardization of the abdominal ultrasound examination

Cited by 9 publications

References 56 publications

Serial monitoring of pancreatic lipase immunoreactivity, C‐reactive protein, abdominal ultrasonography, and clinical severity in dogs with suspected pancreatitis

Serial monitoring of pancreatic lipase immunoreactivity, C‐reactive protein, abdominal ultrasonography, and clinical severity in dogs with suspected pancreatitis

Characterization of clinical presentation, histological features, ultrasonographic findings, and survival in 29 dogs with granulomatous hepatitis

The role of companion animal models in radiopharmaceutical development and translation

Contact Info

Product

Resources

About